Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells.
Human induced pluripotent stem (iPS) cells hold great promise for advancements in developmental biology, cell-based therapy, and modeling of human disease. Here, we examined the use of human iPS cells for modeling inherited metabolic disorders of the liver. Dermal fibroblasts from patients with various inherited metabolic diseases of the liver were used to generate a library of patient-specific human iPS cell lines. Each line was differentiated into hepatocytes using what we believe to be a novel 3-step differentiation protocol in chemically defined conditions. The resulting cells exhibited properties of mature hepatocytes, such as albumin secretion and cytochrome P450 metabolism. Moreover, cells generated from patients with 3 of the inherited metabolic conditions studied in further detail (alpha1-antitrypsin deficiency, familial hypercholesterolemia, and glycogen storage disease type 1a) were found to recapitulate key pathological features of the diseases affecting the patients from which they were derived, such as aggregation of misfolded alpha1-antitrypsin in the endoplasmic reticulum, deficient LDL receptor-mediated cholesterol uptake, and elevated lipid and glycogen accumulation. Therefore, we report a simple and effective platform for hepatocyte generation from patient-specific human iPS cells. These patient-derived hepatocytes demonstrate that it is possible to model diseases whose phenotypes are caused by pathological dysregulation of key processes within adult cells.
Rashid
S Tamir
ST
Laboratory for Regenerative Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.
Corbineau
Sebastien
S
Hannan
Nick
N
Marciniak
Stefan J
SJ
Miranda
Elena
E
Alexander
Graeme
G
Huang-Doran
Isabel
I
Griffin
Julian
J
Ahrlund-Richter
Lars
L
Skepper
Jeremy
J
Semple
Robert
R
Weber
Anne
A
Lomas
David A
DA
Vallier
Ludovic
L
D000328:Adult; D000368:Aged; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D064987:Cell- and Tissue-Based Therapy; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism / Q000494:pharmacology; D005347:Fibroblasts / Q000166:cytology / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism / Q000494:pharmacology; D022781:Hepatocytes / Q000166:cytology / Q000378:metabolism; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology / Q000378:metabolism / Q000502:physiology; D007223:Infant; D008099:Liver / Q000378:metabolism*; D008107:Liver Diseases; D008297:Male; D008875:Middle Aged; D008954:Models, Biological
D006003:Glycogen; D003577:Cytochrome P-450 Enzyme System